2023年第59届美国临床肿瘤学会（ASCO）年会将于美国芝加哥当地时间6月2~6日举行，一年一度的学术盛宴将启。ASCO官网已公布会议日程和摘要题目。【肿瘤资讯】特别整理口头报告专场（Oral Abstract Session）、临床科学研讨会（Clinical Science Symposium），以及壁报讨论专场（Poster Discussion Session）的肉瘤研究，揭秘前沿进展。
口头报告专场（Oral Abstract Session）
摘要号：11500
纳武利尤单抗联合trabectedin用于经治晚期软组织肉瘤（STS）患者的疗效和安全性：德国跨学科肉瘤小组（GISG-15, NitraSarc）的II期试验结果
Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc).
讲者: Peter Reichardt, MD, PhD | HELIOS Klinikum Berlin-Buch, Klinik für Interdisziplinäre Onkologie, Sarkomzentrum Berlin-Brandenburg
摘要号：11501
多柔比星+CTLA-4抑制剂Zalifrelimab+PD-1抑制剂balstilimab治疗晚期/转移性STS患者的单臂、开放标签II期试验
A single-arm, open-label phase 2 trial of doxorubicin plus zalifrelimab, a CTLA-4 inhibitor, with balstilimab, a PD-1 inhibitor, in patients with advanced/metastatic soft tissue sarcomas.
讲者: Breelyn A. Wilky, MD | University of Colorado Anschutz Medical Campus
摘要号：11502
ImmunoSarc2：多柔比星+达卡巴嗪+纳武利尤单抗一线治疗晚期平滑肌肉瘤，西班牙肉瘤小组（GEIS）Ib期试验
ImmunoSarc2: A Spanish Sarcoma Group (GEIS) phase Ib trial of doxorubicin and dacarbazine plus nivolumab in first line treatment of advanced leiomyosarcoma.
讲者: Javier Martin Broto, MD, PhD | Medical Oncology Department, Fundacion Jimenez Diaz University Hospital, Madrid, Spain, Institute of Biomedicine of Seville, University of Seville
摘要号：11503
Cabozantinib+纳武利尤单抗用于既往接受过紫杉类药物治疗的晚期血管肉瘤（AS）患者的多中心II期研究（Alliance A091902）
A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).
讲者: Juneko E. Grilley-Olson, MD | Duke Cancer Institute, Duke University
摘要号：LBA11504
Cabozantinib联合PD-1和CTLA-4抑制剂对比Cabozantinib治疗转移性STS的II期随机试验
Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma.
讲者: Brian Andrew Van Tine, MD | Washington University Siteman Cancer Center
摘要号：11505
Cabozantinib联合替莫唑胺治疗不可切除/转移性平滑肌肉瘤和其他STS患者的II期研究
A phase II study of cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas.
讲者: Mark Agulnik, MD | City of Hope Comprehensive Cancer Center
摘要号：11506
新辅助治疗高危STS的III期随机试验（ISG-STS 1001）：同步放化疗的可行性和抗肿瘤活性
A phase III randomized trial of neo-adjuvant chemotherapy in high-risk soft tissue sarcoma (ISG-STS 1001): Feasibility and activity of concurrent chemotherapy and radiation therapy.
讲者: Elena Palassini, MD | Fondazione IRCCS Istituto Nazionale dei Tumori
摘要号：11507
Lurbinectedin（LURBI）+多柔比星（DOX）治疗STS和平滑肌肉瘤（LMS）的疗效：Ib/II期试验
Efficacy of combination lurbinectedin (LURBI) + doxorubicin (DOX) from the phase 1B soft-tissue sarcoma (STS) lead-in to a randomized phase 2 trial in leiomyosarcoma (LMS).
讲者: Gregory Michael Cote, MD | MGH Cancer Center
摘要号：11508
TTI-621联合多柔比星治疗不可切除/转移性高级别LMS患者的安全性和临床活性：来自低剂量扩展队列的结果
Safety and clinical activity of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma: Results from the low-dose expansion cohort.
讲者: Sujana Movva, MD | Memorial Sloan Kettering Cancer Center
临床科学研讨会
（Clinical Science Symposium）
摘要号：11509
应用循环肿瘤DNA（ctDNA）检测局部STS的MRD
Molecular residual disease (MRD) detection using bespoke circulating tumor DNA (ctDNA) assays in localized soft tissue sarcoma (STS).
讲者: Abdulazeez Salawu, PhD, MBBS, MSc, MRCP | Princess Margaret Cancer Centre, University Health Network
摘要号：11510
tumor-informed MRD检测在肉瘤中的临床价值
The clinical value of tumor-informed minimal residual disease detection in sarcoma
讲者: 尹军强教授 | 中山大学附属第一医院骨肿瘤科
摘要号：11511
高危STS经新辅助化疗（ChT）后的组织病理学反应（HR）：ISG-STS-1001试验分析
Histopathological response (HR) after neoadjuvant chemotherapy (ChT) for high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 trial.
讲者: Sandro Pasquali, MD, PhD | Molecular Pharmacology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
摘要号：11512
基于影像的深度学习模型预测可切除高级别STS患者对新辅助化疗的组织学反应：一项多中心研究
Deep learning with whole slides images to predict histological response to neoadjuvant chemotherapy in patients with resectable high grade soft-tissue sarcomas: A multicenter study.
讲者: Antoine Italiano, MD | Early Phase Trials and Sarcoma Units, Institut Bergonié
壁报讨论专场（Poster Discussion Session）
摘要号：11513 | Poster Bd #447
妊娠对硬纤维瘤病女性的影响：一项国际回顾性观察性研究
Impact of pregnancy in women with desmoid fibromatosis: An international retrospective observational study.
讲者: Marco Fiore, MD, FACS | Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori
摘要号：11514 | Poster Bd #448
DeFi试验中肿瘤体积和T2高信号变化：nirogacestat治疗硬纤维瘤患者的III期随机对照试验
Tumor volume and T2 hyperintensity changes from DeFi: A phase 3, randomized, controlled trial of nirogacestat in patients with desmoid tumors.
讲者: Thierry Alcindor, MD, MSc | McGill University Health Center
摘要号：11515 | Poster Bd #449
AL102治疗硬纤维瘤（DT）的RINGSIDE II/III期试验结果
RINGSIDE phase 2/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results.
讲者: Mrinal M. Gounder, MD | Memorial Sloan Kettering Cancer Center
摘要号：11516 | Poster Bd #450
CTLA-4和PD-1抑制剂双免治疗罕见肿瘤（DART）的II期篮子试验：DT（SWOG S1609，队列27）
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27).
讲者: Young Kwang Chae, MD, MBA | Northwestern University
摘要号：11517 | Poster Bd #451
仑伐替尼+帕博利珠单抗治疗晚期肉瘤患者的探索性研究
A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma.
讲者: Sujana Movva, MD | Memorial Sloan Kettering Cancer Center
摘要号：11518 | Poster Bd #452
Retifanlimab（R）联合吉西他滨和多西他赛（GD）一线治疗晚期STS患者：II期试验中期结果
Interim results of a phase II trial of first line retifanlimab (R) plus gemcitabine and docetaxel (GD) in patients (pts) with advanced soft tissue sarcoma (STS).
讲者: Evan Rosenbaum, MD | Memorial Sloan Kettering Cancer Center
摘要号：11519 | Poster Bd #453
SARC037：1小时输注trabectedin联合低剂量伊立替康治疗复发/难治性尤文肉瘤（ES）的I期研究结果
SARC037: Results of phase I study of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in relapsed/refractory Ewing sarcoma (ES).
讲者: Patrick Grohar | Children's Hospital of Philadelphia
摘要号：11520 | Poster Bd #454
SELISARC：西班牙肉瘤小组（GEIS）在特定肉瘤亚型中进行的selinexor联合吉西他滨的I/II期试验——I期部分的结果
SELISARC: A Spanish Sarcoma Group (GEIS) phase I/II trial of selinexor plus gemcitabine in selected sarcoma subtypes—Results of the phase I part.
讲者: Javier Martin Broto, MD, PhD | Fundacion Jimenez Diaz University Hospital and Health Research Institute-Fundación Jiménez Díaz University Hospital, Autonomous University of Madrid (IIS-FJD, UAM)
摘要号：11521 | Poster Bd #455
NAB-S联合pazopanib治疗晚期STS的I期临床研究
A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS).
讲者: Lee D. Cranmer, MD, PhD | University of Washington, Fred Hutchinson Cancer Center
（本文依照报告日期和出场排序整理，如有错误或遗漏，敬请留言指正。）
https://meetings.asco.org/meetings/2023-asco-annual-meeting/299/program-guide/search?q=Sarcoma
排版编辑：肿瘤资讯-Marie
苏公网安备32059002004080号
